Form 4 AtriCure Inc For: 3 August
- Investing.com
- English (USA)
- English (UK)
- English (Canada)
- English (Australia)
- English (South Africa)
- English (Philippines)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
AtriCure Inc (ATRC)
The AtriCure share price today is 40.21, view NASDAQ ATRC stock exchange data. Track the latest AtriCure share price with real-time updates on ATRC stock performance including market cap, day range, 52-week range and dividend yield. Access ATRC charts, earnings dates and analyst estimates to support your investment decisions.
NASDAQ
Currency in USD
40.21
+0.87(+2.21%)
Real-time Data·
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
39.00
40.38
52 wk Range
25.36
43.18
ATRC is not included in our AI-picked strategies. See which stocks are.
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
39.0040.38
52 wk Range
25.3643.18
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
ATRC Scorecard
Company’s Health
Assesses a company's financial position by analysing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Strong Buy
Price Target
47.33
Upside
+17.72%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
4 analysts have revised their earnings downwards for the upcoming period
- Form 144 AtriCure For: 29 July
- Investing.com
AtriCure receives Investment Bank Analyst Rating Update- Investing.com
Pro
- Form 4 AtriCure Inc For: 3 August
- Investing.com
- Form 144 AtriCure For: 29 July
- Investing.com
- AtriCure receives Investment Bank Analyst Rating Update
- Investing.com
Pro 
Inspire Medical Systems adds AtriCure CEO to board- Investing.com
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Buy
Technical Indicators
Strong Buy
Moving Averages
Strong Buy
Analyst Ratings
8 Buy
2 Hold
0 Sell
Ratings:
10 analysts
Overall Consensus
Buy
Analysts 12-Month Price Target:
Average 47.33
(+17.72% Upside)
AtriCure Inc Earnings Call Summary for Q2/2026
- AtriCure posted Q2 2026 adjusted EPS of $0.18, beating estimates by $0.19, while revenue rose 12.8% YoY to $153.6M; shares fell 6.4% after-hours.
- Gross margin improved 220bps to 77.2%; company raised full-year adjusted EBITDA guidance to $85M-$89M and expects positive net income for 2026.
- Pain management revenue surged 27% driven by CryoSphere MAX adoption; minimally invasive ablation remained pressured amid market shift to PFA catheters.
- Full-year revenue guidance set at $602M-$610M (12.5%-14% growth); Q3 expected to decline 1%-2% sequentially before Q4 rebound.
- BoxX-NoAF trial enrollment on track to complete by end-2026 with data expected H1 2027; PMA filing anticipated alongside May 2027 medical meeting presentation.
Last Updated: 24-07-2026, 03:02 am
Read Full TranscriptEarnings
Latest Release
23-07-2026
EPS / Forecast
0.18 / -0.01
Revenue / Forecast
153.6M / 151.84M
Compare ATRC to Peers and Sector
Metrics to compare | ATRC | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipATRCPeersSector | |
|---|---|---|---|---|
P/E Ratio | 190.1x | 12.9x | −0.4x | |
PEG Ratio | 1.49 | 0.08 | 0.00 | |
Price/Book | 3.9x | 2.1x | 2.6x | |
Price / LTM Sales | 3.5x | 2.3x | 3.0x | |
Upside (Analyst Target) | 27.1% | 41.3% | 51.8% | |
Fair Value Upside | Unlock | 16.7% | 7.2% | Unlock |
AtriCure, Inc. engages in the development, manufacture, and sale of devices for surgical ablation of cardiac tissue, exclusion of the left atrial appendage, and temporarily blocking pain by ablating peripheral nerves to medical centers in the United States, the Asia-Pacific, and internationally. It offers Isolator Synergy Ablation System clamps, a single-use disposable radio frequency products; multifunctional pens and linear ablation devices, a single-use disposable RF products for the treatment of cardiac arrhythmias; cryoICE Cryoablation System that enables the user to make linear ablations of varied lengths; and EPi-Sense Systems, a single-use disposable device used for the treatment of symptomatic, drug-refractory, and long-standing persistent atrial fibrillation. It also provides cryoSPHERE probe, which provides temporary pain relief by applying cryothermic energy to targeted intercoastal peripheral nerves in the ribcage; AtriClip System, an implantable device coupled to a single-use disposable applier; cryoXT probes, a cryoablation device designed specifically for Cryo Nerve Block therapy; LARIAT System, a solution for soft-tissue closure; Lumitip dissectors to separate tissues to provide access to key anatomical structures that are targeted for ablation; Glidepath guides for placement of clamps; and Subtle Cannula’s to support access for EPi-Sense catheters. In addition, the company sells various reusable cardiac surgery instruments. It markets and sells its products through independent distributors and direct sales personnel. The company was incorporated in 2000 and is headquartered in Mason, Ohio.
Ownership
Ownership Overview
Top Holders
FAQ
What Is the AtriCure (ATRC) Share Price Today?
The AtriCure share price today is 40.21.
What is the current AtriCure (ATRC) share price and day range?
As of 06-08-2026, the AtriCure share price is 40.21, with a previous close of 39.34. The share price has ranged from 39.00 to 40.38 today, while the 52-week range spans from 25.36 to 43.18.
What Is the AtriCure Market Cap?
As of today, AtriCure market cap is 2.05B.
What Is the AtriCure (ATRC) Share Price Target?
The average 12-month share price target for AtriCure is 47.33, with a high estimate of 55 and a low estimate of 36. 8 analysts recommend buying, while 0 suggest selling, with an overall rating of Buy and +17.72% Upside potential.
What Is AtriCure's Earnings Per Share (TTM)?
The AtriCure EPS (TTM) is 0.21.
When Is the Next AtriCure Earnings Date?
AtriCure will release its next earnings report on 04-11-2026.
From a Technical Analysis Perspective, Is ATRC a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Buy.
What Stock Exchange Does AtriCure Trade On?
AtriCure is listed and trades on the Nasdaq Stock Exchange.
What Is the Stock Symbol for AtriCure?
The stock symbol for AtriCure is "ATRC."
How Many Times Has AtriCure Stock Split?
AtriCure has split 0 times.
How Many Employees Does AtriCure Have?
AtriCure has 1350 employees.
What Is the ATRC Premarket Price?
ATRC's last pre-market stock price is 40.00. The pre-market share volume is 240.00, and the stock has changed by 0.66, or 1.68%.
What Is the ATRC After Hours Price?
ATRC's last after hours stock price is 39.65, the stock has changed by 0.31, or 0.79%.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.